We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    05508750
Previous Study | Return to List | Next Study

Growth and Safety Clinical Trial on a New Infant Formula

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05508750
Recruitment Status : Recruiting
First Posted : August 19, 2022
Last Update Posted : September 29, 2022
Information provided by (Responsible Party):
Jovie USA, LLC

Brief Summary:
The aim of this study is to assess age-appropriate growth of healthy infants fed a new infant formula. In this randomized, controlled trial, healthy, term, formula-fed infants will be randomized to one of two infant formulas: a standard, commercially-available infant formula for term infants or the new infant formula for term infants for 16 weeks. A reference group of human milk-fed infants will also be enrolled. This study is designed in accordance with Good Clinical Practice guidelines and the requirements of the Code of Federal Regulations, 21CFR106.96. This study allows caregivers to participate completely from the comfort of their own home.

Condition or disease Intervention/treatment Phase
Weight Gain Other: New Infant Formula Other: Commercial Infant Formula Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A decentralized, randomized, controlled trial of healthy term breastfed and formula-fed infants for 16 weeks
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: A Randomized, Controlled Trial Evaluating Growth and Safety in Infants Fed a New Infant Formula
Actual Study Start Date : September 21, 2022
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: New Infant Formula
New infant formula for healthy term infants
Other: New Infant Formula
New infant formula fed daily ad libitum

Active Comparator: Commercial Infant Formula
Standard, commercially available infant formula for healthy term infants
Other: Commercial Infant Formula
Commercially available infant formula fed daily ad libitum

No Intervention: Human Milk
Breastfed infants serve as a reference group

Primary Outcome Measures :
  1. Weight gain from baseline to 16 weeks feeding [ Time Frame: 16 weeks ]
    Weight gain g/day

Secondary Outcome Measures :
  1. Length gain from baseline to 16 weeks feeding [ Time Frame: 16 weeks ]
    Length gain

  2. Head Circumference gain from baseline to 16 weeks feeding [ Time Frame: 16 weeks ]
    Head Circumference gain

  3. Volume of formula consumed during 3-consecutive day intervals [ Time Frame: 16 weeks ]
    Volume of formula consumed

Other Outcome Measures:
  1. Assessment of AEs [ Time Frame: 16 weeks ]
    AEs reported during the study

  2. Caregiver report of tolerance obtained during 3-consecutive day intervals [ Time Frame: 16 weeks ]
    Caregiver report of fussiness, gassiness, and spitting up

  3. Caregiver report of stool characteristics obtained during 3-consecutive day intervals [ Time Frame: 16 weeks ]
    Caregiver report of stool consistency, color, and frequency

  4. Stool collection for microbiome testing [ Time Frame: 16 weeks ]
    Stool collection for microbiome testing at week 16 of feeding

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   0 Days to 14 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Normal term infant (37-42 weeks gestation at birth)
  • Infant <15 (+3) days of age at first study feeding, Birth constitutes day 0
  • Infant birth weight of ≥2500 g (5.5 lbs.)
  • Healthy Infant
  • Caregiver who has previously decided to exclusively feed infant formula or exclusively breastfeed and is willing to continue with current feeding method throughout the study (breastfeeding or formula feeding)
  • Caregiver willing to conform to protocol requirements (e.g. measuring, feeding, completion of food intake and tolerance diaries, and reporting of AEs)
  • Caregiver willing and able to sign informed consent

Exclusion Criteria:

  • Infant born in multiple birth (i.e., twins, triplets, etc.)
  • Infant born with medical complications (e.g., neurological, cerebral palsy, etc.)
  • Infant with family history (parents or siblings) of confirmed Milk or Soy allergies
  • Infant with failure to thrive, fever, any GI tract abnormalities (e.g., short gut, gastroesophageal reflux, etc.), any congenital illness or malformation that may affect infant feeding or normal growth
  • Caregiver intent to feed non-study formula or solid food during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05508750

Layout table for location contacts
Contact: Jan van Marwijk, CEO Jovie USA LLC +1 847-337-2615 j.vanmarwijk@jovieusa.com

Layout table for location information
United States, New York
ObvioHealth Recruiting
New York, New York, United States, 10001
Contact: Parth Shah, Principle Investigator and Medical Director    888-638-6889    joviestudy@obviohealth.com   
Sponsors and Collaborators
Jovie USA, LLC
Layout table for investigator information
Principal Investigator: Parth Shah, MD FAPCR ObvioHealth
Study Director: Dawn Ross, Director Clinical Project Management IQVIA RDS Inc.
Layout table for additonal information
Responsible Party: Jovie USA, LLC
ClinicalTrials.gov Identifier: NCT05508750    
Other Study ID Numbers: IQV-JOV-001
First Posted: August 19, 2022    Key Record Dates
Last Update Posted: September 29, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jovie USA, LLC:
Additional relevant MeSH terms:
Layout table for MeSH terms
Weight Gain
Body Weight Changes
Body Weight